Survodutide (BI 456906) Clinical Trial Overview and Mechanism

Traditional incretin therapies such as semaglutide operate almost exclusively through glycemic control and appetite suppression via GLP-1 receptors in the pancreas, vagus nerve, and hypothalamus. Survodutide integrates a potent glucagon receptor agonism designed to recruit the liver's intrinsic metabolic machinery:

1. Hepatic Lipolysis and Beta-Oxidation: Glucagon receptor signaling in hepatocytes activates cyclic AMP (cAMP) and protein kinase A (PKA), triggering mitochondrial beta-oxidation of fatty acids and shutting down de novo lipogenesis. This rapidly depletes intrahepatic fat droplets (steatosis).
2. Thermogenesis and Energy Expenditure: GCGR activation stimulates basal metabolic rate and hepatic energy expenditure, preventing the compensatory drop in resting metabolic rate that typically stalls diet-induced weight loss.
3. GLP-1 Counter-Regulation: Glucagon alone is diabetogenic (raising blood glucose via glycogenolysis). Survodutide's balanced GLP-1 receptor affinity directly counterbalances glucagon's glycemic output by stimulating glucose-dependent insulin secretion and suppressing inappropriate postprandial glucose surges.

This dual action allows survodutide to act as a metabolic furnace in hepatic tissue while preserving tight glycemic control.

Metabolic dysfunction-associated steatohepatitis (formerly NASH) affects up to 5% to 7% of adults and represents a leading cause of liver cirrhosis and liver transplantation.

In a randomized, double-blind, placebo-controlled Phase 2 trial (Sanyal et al., NEJM 2024; NCT04771273):

• Cohort: 293 adults with biopsy-confirmed MASH and fibrosis stages F1 to F3.
• Treatment Arms: Survodutide weekly doses (2.4 mg, 4.8 mg, or 6.0 mg) vs placebo for 48 weeks.
• MASH Improvement: 83.0% of patients in the 4.8 mg survodutide group achieved histological improvement of MASH without worsening of fibrosis, compared to 18.2% in the placebo group (odds ratio 21.6; p < 0.001).
• Fibrosis Improvement: 64.5% of patients in the 4.8 mg group achieved at least a 1-stage improvement in liver fibrosis without worsening of MASH, compared to 25.9% on placebo.
• Hepatic Steatosis: Magnetic resonance imaging (MRI-PDFF) demonstrated a relative liver fat reduction of up to 87% on survodutide, with over 60% of patients normalizing liver fat to <5%.

The US Food and Drug Administration (FDA) granted Survodutide Fast Track designation for MASH with fibrosis and Breakthrough Therapy designation.

In a 46-week Phase 2 randomized trial in individuals with overweight or obesity without diabetes published in The Lancet Diabetes & Endocrinology (le Roux et al., 2024):

• Participants achieved up to 18.7% mean body weight loss with survodutide 4.8 mg weekly, compared to 2.8% for placebo.
• Over 82% of participants receiving survodutide achieved ≥10% weight loss, and nearly 40% achieved ≥20% weight loss.
• Weight loss had not plateaued at week 46, indicating substantial ongoing efficacy beyond 1 year.

The SYNCHRONIZE Phase 3 Clinical Architecture

Boehringer Ingelheim launched five pivotal Phase 3 trials within the SYNCHRONIZE program:

• SYNCHRONIZE-1 (NCT06066515): Evaluation of survodutide in non-diabetic obesity (76 weeks).
• SYNCHRONIZE-2 (NCT06066528): Evaluation in individuals with obesity and type 2 diabetes.
• SYNCHRONIZE-CVOT (NCT06077864): Long-term cardiovascular outcomes trial.

While tirzepatide remains the leading approved incretin therapy and retatrutide represents the highest raw weight-loss investigational compound, survodutide is uniquely optimized for direct liver tissue preservation and hepatic fibrosis regression.

Consistent with other GLP-1 and glucagon receptor agonists, adverse events in survodutide trials were primarily gastrointestinal:

• Nausea and Vomiting: Nausea occurred in ~66% of patients on the highest dose arms (vs 23% on placebo), with vomiting in ~25%. Over 90% of events were mild to moderate and resolved with continued treatment or dose adjustments.
• Discontinuation Rates: In Phase 2 trials, discontinuation due to adverse events was ~20% at the 4.8 mg maintenance dose, underscoring the importance of slow dose titration in ongoing Phase 3 trials.
• Cardiovascular Safety: Mean resting pulse increased by approximately 2 to 4 beats per minute, consistent with class effects; no clinically meaningful arrhythmias or adverse cardiovascular signals were identified.

What is survodutide? Survodutide (BI 456906) is an investigational dual glucagon receptor (GCGR) and GLP-1 receptor agonist developed jointly by Boehringer Ingelheim and Zealand Pharma for the treatment of MASH and obesity.

How effective is survodutide for MASH (fatty liver disease)? In Phase 2 biopsy trials published in the New England Journal of Medicine (2024), 83% of patients achieved resolution of MASH without worsening of fibrosis, and 64.5% achieved improvement in liver fibrosis stages F1 to F3.

How does survodutide cause weight loss? Survodutide activates GLP-1 receptors to slow gastric emptying and suppress central appetite, while simultaneously activating hepatic glucagon receptors to stimulate fatty acid oxidation, increase thermogenesis, and raise energy expenditure.

How does survodutide compare to retatrutide? Both compounds incorporate glucagon receptor agonism for hepatic fat clearing. However, survodutide is a dual agonist (GLP-1 + Glucagon), whereas retatrutide is a triple agonist (GIP + GLP-1 + Glucagon). Survodutide's development has focused heavily on liver fibrosis and MASH resolution.

Is survodutide approved by the FDA? No. As of 2026, survodutide is an investigational compound in Phase 3 clinical trials (the SYNCHRONIZE and LIVERCISE programs) and has not received FDA or EMA approval.